Loading company financials…
NYSE · Pharmaceutical Preparations · CIK 0001551152
$256.46
+0.38% · delayed 15 min
$452.74B market value
What this company does
AbbVie develops and makes medicines. It took in $61.16B last year, which makes it a very large company. Of every dollar it sells, about 7 cents is left as profit.
Financial health
Generally healthy, with a few things to watch.
From AbbVie Inc.'s FY2025 annual filing · share price scored separately
Every check behind the three models, and what each one tests
Measured against FY2024, from the 10-K
Improved: +8.6%
$56.33B to $61.16B
Deteriorated: -5.3%
$5.52B to $5.23B
Changed: +24.6%
$974.0M to $1.21B
It makes a profit rather than burning through money.
$4.23B earned last year
Day-to-day operations generate real cash, not just accounting profit.
$19.03B cash from operations
It passes almost every standard check of financial strength.
Piotroski 8/9
More bills fall due within a year than it holds in short-term assets.
0.67x cover on near-term bills
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 11% a year for the next 10 years. Over the last 10 years it grew by about 10% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 7 cents of every dollar of sales as profit, earning $4.23B last year.
What it earns, what it keeps, and what it costs to run — all from the same filing
Whether the dividend is covered by what the business actually earns
It paid out more than it earned — 276 cents for every dollar of profit. A payment above earnings has to be funded from somewhere else, so it is worth checking whether that can continue. It paid out 61% of the cash its operations generated. It has paid in each of the last 12 years.
WeakNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $4.23B and generated $19.03B of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Major event announcement(8-K) | 2026-09-03 | 2026-09-03 |
| Major event announcement(8-K) | 2026-08-18 | 2026-08-18 |
Financial figures are from ABBV's 10-K for fiscal year 2025 (period ending 2025-12-31), reported under the US GAAP taxonomy. View the source filing. Total liabilities were not tagged directly and were calculated as assets minus equity.
8 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
2.52
In the grey zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.86
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
6 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 8% and 13%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 1.0% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Slowly. Sales grew 8.6% last year.
Manageable, but notable. Clearing its debt would take about 3.2 years of cash flow. For every $1 it owes, it owns $0.98 in assets.
Expensive. Investors pay $107.1 for every $1 of yearly profit, so a lot of future growth is already priced in.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
At a glance
| Major event announcement(8-K) | 2026-08-05 | 2026-08-04 |
| Quarterly report(10-Q) | 2026-08-03 | 2026-06-30 |
| Major event announcement(8-K) | 2026-07-31 | 2026-07-31 |
| Major event announcement(8-K) | 2026-07-06 | 2026-07-06 |
| Major event announcement(8-K) | 2026-06-22 | 2026-06-18 |
| Major event announcement(8-K) | 2026-05-12 | 2026-05-08 |
| Quarterly report(10-Q) | 2026-05-08 | 2026-03-31 |
| Major event announcement(8-K) | 2026-04-29 | 2026-04-29 |
| Major event announcement(8-K) | 2026-04-03 | 2026-04-03 |
| Shareholder voting information(DEF 14A) | 2026-03-23 | 2026-05-08 |
| Major event announcement(8-K) | 2026-03-04 | 2026-03-04 |
| Major event announcement(8-K) | 2026-02-26 | 2026-02-24 |
| Annual report(10-K) | 2026-02-20 | 2025-12-31 |
| Major event announcement(8-K) | 2026-02-04 | 2026-02-04 |
| Major event announcement(8-K) | 2026-01-07 | 2026-01-07 |
| Quarterly report(10-Q) | 2025-11-04 | 2025-09-30 |
| Major event announcement(8-K) | 2025-10-31 | 2025-10-31 |
| Major event announcement(8-K) | 2025-10-03 | 2025-10-03 |
Coverage from the last 30 days
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo Finance ·
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
Yahoo Finance ·
AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing?
Yahoo Finance ·
The Zacks Analyst Blog Highlights Amazon.com, AbbVie, Alibaba and Lulu's Fashion Lounge
Yahoo Finance ·
Here Are 5 ETFs That Retirees Use to Skip Stock Picking Entirely
Yahoo Finance ·
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
Yahoo Finance ·
AbbVie (ABBV) Reports Positive Phase 3 Results For Etentamig In Multiple Myeloma
Yahoo Finance ·
AbbVie (ABBV)’s Blood Cancer Success Adds Weight to its Pipeline Story
Yahoo Finance ·
The "Untouchable" List: Stocks That Short Sellers Won't Dare Bet Against
Yahoo Finance ·
Top Analyst Reports for Amazon, AbbVie & Alibaba
Yahoo Finance ·
Sector Update: Healthcare Stocks Edge Higher Late Afternoon
Yahoo Finance ·
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
Yahoo Finance ·
Primary sources and further research